AUTL today
$1.19-$0.05 (-3.64%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minDescending Triangle
Daily trend turns up above $1.69
Key levels
Resistance$1.50
Resistance$1.38
Support$1.18
Latest news & SEC filings
ProductAutolus Therapeutics reports longer-term CARLYSLE Phase 1 follow-up results
EarningsAutolus Therapeutics Posts Q3 2026 Financials
EarningsAutolus Therapeutics holds Q3 2026 earnings call
SEC FilingAutolus Therapeutics plc filed a report on a major company event (Form 8-K)
All AUTL news →About Autolus Therapeutics
Autolus Therapeutics is a biopharmaceutical company that develops, manufactures and sells engineered T cell therapies for cancer and autoimmune diseases. Its approved product, AUCATZYL (obe-cel), treats adults whose leukemia of the B-cell lineage has returned or stopped responding to treatment, and it is sold in the United States and United Kingdom. The company also runs clinical programs testing obe-cel in childhood leukemia, B-cell non-Hodgkin lymphoma, lupus nephritis and multiple sclerosis. It operates a manufacturing site in Stevenage, United Kingdom.
Based on the company's 10-K filed Mar 27, 2026.
Nasdaq · Healthcare
Autolus Therapeutics plc (AUTL)
What Is the Price Target for AUTL?
SEPT Low Target
$10.00
SEPT Mid Target
$10.00
SEPT High Target
$10.00
Analyst Consensus
$10.00
Is AUTL a Buy or Sell Right Now?
Thesis
- •Revenue growing 644.9% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AUTL.
Start Free Trial →Is AUTL Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$10.00
17
Moat Score
NONE
2/9
Piotroski Score
-3.4
Altman Z-Score
What Is Smart Money Doing with AUTL?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AUTL Growth Story
Revenue YoY
644.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-25.58%
FCF Growth YoY
-32.5%
Revenue Trend
ACCELERATING
Dark Pool Trades for AUTL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AUTL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:59:56 | $1.20 | 1,000 | $$1K | BUY |
| 20:59:51 | $1.20 | 1,900 | $$2K | BUY |
| 20:59:51 | $1.20 | 1,000 | $$1K | BUY |
| 20:59:02 | $1.20 | 1,100 | $$1K | BUY |
| 20:58:48 | $1.20 | 1,200 | $$1K | BUY |
5 dark pool trades shown · $$7K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Autolus Therapeutics plc (AUTL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AUTL — frequently asked questions
What is AUTL stock price today?
Autolus Therapeutics plc (AUTL) is at $1.19, down 3.64% (-$0.05) at the Nov 12, 2026 close.
Why is AUTL stock moving today?
Latest AUTL news — Nov 10, 2026: Autolus Therapeutics reports longer-term CARLYSLE Phase 1 follow-up results · Nov 10, 2026: Autolus Therapeutics Posts Q3 2026 Financials
Why did AUTL stock move on Nov 10, 2026?
Autolus Therapeutics shares closed at $1.32, up 9.09% on heavy volume of 6.7 million shares, after the company reported longer-term CARLYSLE Phase 1 follow-up results showing most participants reached DORIS with meaningful SLEDAI-2K gains despite severe disease activity at enrollment. The company also guided fiscal 2026 AUCATZYL net product revenue above $150 million, a high-impact bullish signal.
What is the AUTL price target?
The average analyst price target for AUTL is $10.00, ranging from $10 to $10, based on 2 analysts.
What do analysts rate AUTL?
Analyst ratings for AUTL: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did AUTL beat earnings?
AUTL last reported on Nov 10, 2026: EPS -$0.21 vs -$0.18 expected — a miss of 16.7%.
Does AUTL pay a dividend?
AUTL does not currently pay a dividend.
What are AUTL support and resistance levels?
Support: $1.18. Resistance: $1.38, $1.50, $1.65.
What are insiders doing with AUTL?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on AUTL?
Nov 10, 2026: Autolus Therapeutics reports longer-term CARLYSLE Phase 1 follow-up results · Nov 10, 2026: Autolus Therapeutics Posts Q3 2026 Financials · Nov 10, 2026: Autolus Therapeutics holds Q3 2026 earnings call